|
LIVE WEBINAR: Tuesday, April 27, 2021, 5:00 PM – 6:30 PM Eastern Time
Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers13th Annual Oncology Grand Rounds NCPD Webinar SeriesGynecologic Cancers
Faculty
Robert L Coleman, MD Chief Scientific Officer US Oncology Research Gynecologic Oncology The Woodlands, Texas Thomas J Herzog, MD Paul and Carolyn Flory Professor Deputy Director, University of Cincinnati Cancer Center Vice-Chair, Quality and Safety Department of Obstetrics and Gynecology University of Cincinnati Medical Center Associate Director, GOG Partners Cincinnati, Ohio Krishnansu S Tewari, MD Professor and Division Director Division of Gynecologic Oncology University of California, Irvine Irvine, California Nurse Case Presentations By
Paula J Anastasia, MN, RN, AOCN GYN Oncology Advanced Practice Nurse University of California, Los Angeles Los Angeles, California Courtney Arn, CNP The James Cancer Hospital and Solove Research Institute The Ohio State University Columbus, Ohio Kimberly A Spickes, MNSc, RN, APRN, OCN, ACNP-BC Nurse Practitioner UAMS Division of Gynecologic Oncology University of Arkansas for Medical Sciences Little Rock, Arkansas Moderator Neil Love, MD Research To Practice Miami, Florida Tuesday, April 27, 2021 Topics to Be Discussed
Target Audience
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCPD Designation Statements This educational activity for 1.5 contact hours is provided by RTP. This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours. To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity. Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2021/GynOnc/ILNA Unlabeled/Unapproved Uses Notice There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Coleman – Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure Inc, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics. Dr Herzog – Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gradalis Inc, GlaxoSmithKline, Merck; Data and Safety Monitoring Board/Committee: Corcept Therapeutics, Incyte Corporation. Dr Tewari – Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company. CONTRIBUTING NURSES — Ms Anastasia, Ms Arn and Ms Spickes had no relevant conflicts of interest to disclose. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc. RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline and Merck. |